New drug study aims to shrink enlarged spleens in blood disorder patients
NCT ID NCT07249606
Summary
This study observes how well the drug momelotinib works for people with myelofibrosis, a serious bone marrow disorder, in real-world medical settings. Researchers will follow 93 adult patients who have an enlarged spleen to see if the treatment reduces spleen size by at least half within six months. The study collects data from patients already receiving this medication as part of their standard care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS，MF are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.